Abstract
Alzheimer's disease (AD), a central cause of dementia, is characterized by the accumulation of amyloid β-peptide (Aβ) peptides in the brain. P-glycoprotein (P-gp), a highly expressed protein in the BBB, plays a fundamental role in transporting Aβ from the brain to the blood and protecting the blood-brain barrier (BBB). The dysfunction or decreased abundance of this transporting protein is associated with the accumulation of Aβ, leading to dementia and cognitive deficits. In this review article, we consolidate the existing literature on the impact of P-gp in the pathophysiology and therapy of AD. Current evidence claims that p-gp is involved in AD pathology and that enhancing the activity of this transporter may be a promising therapeutic approach to hinder AD progression. There is also a growing interest in P-gp as a potential therapeutic target for AD. Hence, ongoing clinical trials and research should investigate P-gp inhibitor efficacy as a therapeutic approach for improving AD drug delivery to the brain and treatment outcomes.
Keywords: Amyloid β-peptide, P-glycoprotein, blood-brain barrier, Alzheimer’s disease, pathology, therapeutic targeting.
Letters in Drug Design & Discovery
Title:P-glycoproteins in the Pathology and Treatment of Alzheimer's Disease
Volume: 21 Issue: 16
Author(s): Raghad H. Aljohani, Nouf F. Alruwali, Shorooq M. Alrashedi, Somaya M. Yousef, Shahad T. Alobaidan, Nehal M. Elsherbiny and Hebatallah H. Atteia*
Affiliation:
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia
- Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Sharkia, Egypt
Keywords: Amyloid β-peptide, P-glycoprotein, blood-brain barrier, Alzheimer’s disease, pathology, therapeutic targeting.
Abstract: Alzheimer's disease (AD), a central cause of dementia, is characterized by the accumulation of amyloid β-peptide (Aβ) peptides in the brain. P-glycoprotein (P-gp), a highly expressed protein in the BBB, plays a fundamental role in transporting Aβ from the brain to the blood and protecting the blood-brain barrier (BBB). The dysfunction or decreased abundance of this transporting protein is associated with the accumulation of Aβ, leading to dementia and cognitive deficits. In this review article, we consolidate the existing literature on the impact of P-gp in the pathophysiology and therapy of AD. Current evidence claims that p-gp is involved in AD pathology and that enhancing the activity of this transporter may be a promising therapeutic approach to hinder AD progression. There is also a growing interest in P-gp as a potential therapeutic target for AD. Hence, ongoing clinical trials and research should investigate P-gp inhibitor efficacy as a therapeutic approach for improving AD drug delivery to the brain and treatment outcomes.
Export Options
About this article
Cite this article as:
Aljohani H. Raghad, Alruwali F. Nouf, Alrashedi M. Shorooq, Yousef M. Somaya, Alobaidan T. Shahad, Elsherbiny M. Nehal and Atteia H. Hebatallah*, P-glycoproteins in the Pathology and Treatment of Alzheimer's Disease, Letters in Drug Design & Discovery 2024; 21 (16) . https://dx.doi.org/10.2174/0115701808293022240216070603
DOI https://dx.doi.org/10.2174/0115701808293022240216070603 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Call for Papers in Thematic Issues
Navigating the Frontier: Probiotics' Promising Path in Combatting Viral Respiratory Infections, Spotlight on Coronaviridae.
Probiotics, well-known for their role in gut health, show promise in preventing and managing respiratory virus infections, particularly in children and at-risk populations. However, the profound influence of novel pathogenic viral RTIs such as coronaviruses has reshaped perspectives on the potential of probiotics. Despite their potential, significant gaps remain in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets Regulation of Neurogenesis and Angiogenesis in Depression
Current Neurovascular Research HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Neural Mechanisms of Exercise: Effects on Gut Miccrobiota and Depression
CNS & Neurological Disorders - Drug Targets Targeting HIV-1 gp41-induced Fusion and Pathogenesis for Anti-viral Therapy
Current Topics in Medicinal Chemistry Quantum Pharmacology for Infectious Diseases: A Molecular Connectivity Approach
Current Computer-Aided Drug Design Cytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A ReviewCytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A Review
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Neonatal Pain, Still Searching for the Optimal Approach
Current Pharmaceutical Design Bis-iodine-labeled Curcumin as a Potential CT Imaging Agent for β-amyloid Plaques in the Brain
CNS & Neurological Disorders - Drug Targets Antibody Based Therapies in Acute Leukemia
Current Drug Targets Study of Common Bacterial and Fungal Pathogens in Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study
Infectious Disorders - Drug Targets Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders
Current Molecular Medicine Traumatic Brain Injury: Central and Peripheral Role of α7 Nicotinic Acetylcholine Receptors
Current Drug Targets